https://www.businesswire.com/news/home/20250424007807/en/FORE-Biotherapeutics-Presents-New-Plixorafenib-Results-at-AACR-2025-Demonstrating-Pharmacodynamic-Effect-in-Clinical-Tumor-Biopsies-and-Decreased-V600E-Mutant-Allele-Frequency-in-ctDNA-of-85-of-Patients
FORE Biotherapeutics Presents New Plixorafenib Results at AACR 2025 Demonstrating Pharmacodynamic...
FORE Biotherapeutics, a registration stage biotherapeutics company dedicated to developing targeted therapies to treat patients with cancer, today presented ...
aacr 2025forebiotherapeuticspresentsnew